Back to news

Rapid Micro Biosystems Signs Definitive Agreement to be Acquired by Merck KGaA, Darmstadt, Germany

Globe Newswire•16/11/2026•09:26 ET
0

Key Highlights

  • ➤Merck KGaA agreed to acquire Rapid Micro Biosystems for $0.75 per share in cash.
  • ➤Transaction expected to close in December 2026, subject to tender and customary conditions.
  • ➤Rapid Micro Biosystems will join Merck KGaA’s Life Science business after completion.
  • ➤Rapid’s Growth Direct platform automates microbial quality-control workflows for pharmaceutical manufacturers.

Expert Statements

Robert Spignesi, President and CEO of Rapid Micro Biosystems

“Over the past 18 months, we have built a strong partnership with Merck KGaA, Darmstadt, Germany, centered on a shared commitment to innovation and helping customers modernize and automate their quality-control workflows”

Robert Spignesi, President and CEO of Rapid Micro Biosystems

“Rapid Micro has established the Growth Direct platform as the leading solution for automating microbial quality control, with most of the world's top pharmaceutical manufacturers as customers.”

Robert Spignesi, President and CEO of Rapid Micro Biosystems

“We are confident that joining the Life Science business of Merck KGaA, Darmstadt, Germany will significantly expand the Growth Direct platform’s reach and more fully serve our combined global customer base.”

Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany

“Quality control is essential to the reliable manufacture of medicines,”

Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany

“Our customers need reliable results faster, more efficient quality-control workflows and robust data integrity to support regulatory compliance.”

Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany

“Rapid Micro Biosystems will strengthen our ability to meet those needs, building on our existing offering and bringing greater automation to a critical step in pharmaceutical manufacturing.”

LEXINGTON, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced it has signed a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, has agreed to acquire, subject to the terms and conditions set forth in the agreement, all outstanding shares of Rapid Micro Biosystems at a price of $0.75 per share in an all-cash transaction.

"Over the past 18 months, we have built a strong partnership with Merck KGaA, Darmstadt, Germany, centered on a shared commitment to innovation and helping customers modernize and automate their quality-control workflows,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems. “Rapid Micro has established the Growth Direct platform as the leading solution for automating microbial quality control, with most of the world's top pharmaceutical manufacturers as customers. We are confident that joining the Life Science business of Merck KGaA, Darmstadt, Germany will significantly expand the Growth Direct platform’s reach and more fully serve our combined global customer base."

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in